Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
Blood Coagul Fibrinolysis
; 23(4): 331-4, 2012 Jun.
Article
en En
| MEDLINE
| ID: mdl-22343685
ABSTRACT
This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in which splenectomy was not possible due to the persistence of a low platelet count despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) and platelet transfusion treatment. As an attempt to increase platelet count prior to performing splenectomy, the thrombopoietin receptor agonist, romiplostim, was administered in combination with steroids and IVIG. A single administration of romiplostim was found to be markedly effective, allowing a rapid and notable platelet increase, required for a well tolerated splenectomy. This case confirms the potent activity of romiplostim in ITP, and indicates that patients with recurrent primary ITP who are unresponsive to conventional immunosuppressive therapy may benefit from the addition of a short course of romiplostim.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esteroides
/
Trombopoyetina
/
Plaquetas
/
Proteínas Recombinantes de Fusión
/
Inmunoglobulinas
/
Receptores Fc
/
Púrpura Trombocitopénica Idiopática
/
Receptores de Trombopoyetina
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Blood Coagul Fibrinolysis
Asunto de la revista:
ANGIOLOGIA
/
HEMATOLOGIA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Italia